九安醫療(002432.SZ)封漲停板 試劑盒可檢測出奧密克戎變異毒株
格隆匯1月7日丨九安醫療今日盤中封漲停板,報價52.38元,最新市值251億元。九安醫療昨晚公吿,公司於1月5日晚收到美國FDA安排的美國國立衞生研究院的RADx項目就iHealth新冠抗原家用自測OTC試劑盒針對新冠病毒奧密克戎變異毒株的測試性能實驗報吿。報吿顯示,iHealth新冠抗原家用自測OTC試劑盒在實驗中100%檢測出了最大CT值為21.59(n=5)的新冠病毒奧密克戎變異毒株活性病毒樣本。九安醫療在互動平台表示,公司的試劑盒產品獲得的是美國FDA EUA授權,可以在美國銷售,國內沒有獲得授權無法銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.